title: Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.
authors: *Department of Medical Oncology, Cantonal Hospital, Luzern, Switzerland; †Department of Pathology, Cantonal Hospital, Luzern, Switzerland; and ‡Department of Nuclear Medicine, Cantonal Hospital, Luzern, Switzerland.
authors: Daniela
authors: D
authors: Weiler
authors: Joachim
authors: J
authors: Diebold
authors: Klaus
authors: K
authors: Strobel
authors: Stefan
authors: S
authors: Aebi
authors: Oliver
authors: O
authors: Gautschi
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D008453:Maytansine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D021141:Nucleic Acid Amplification Techniques; D049268:Positron-Emission Tomography; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D000068878:Trastuzumab
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human